A manufacturer of a Schedule II product entered into sequential patent settlement agreements that included product supply obligations. Following allegations from its partners that the manufacturer was using the patent settlements to adversely affect competition, CRA’s analysis demonstrated that there was no anticompetitive effect and that the supply agreements enhanced efficiency and competition, particularly when considering the Drug Enforcement Agency’s quota system for active ingredient supply for Schedule II products.
The Media Show - Reporting on the Abuse of Power
Philip Marsden discusses some of the ramifications of the UK Government’s approach to Digital Regulation, ahead of the Queen’s Speech this week. For more...